{"id":106,"date":"2025-06-14T10:00:00","date_gmt":"2025-06-14T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=106"},"modified":"2025-09-01T02:30:08","modified_gmt":"2025-09-01T02:30:08","slug":"technology-collaboration-cspc-and-astrazeneca-enters-a-5-3-billion-usd-collaboration-on-ai-enabled-drug-research","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/106.html","title":{"rendered":"[Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug research"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-06-13 (June 13, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: CSPC (CSPC Pharmaceuticals Group Limited.&nbsp;, China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee: AstraZeneca\uff08UK\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Collaboration Object: AI-enabled, &nbsp;advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Collaboration:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases. The research will be carried out by CSPC, in Shijiazhuang City and will utilise their AI-driven, dual-engine efficient drug discovery platform.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AstraZeneca will have rights to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under this agreement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment and near term payment&nbsp; $110 million;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development milestone payments up to &nbsp;$1.62 billion;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sales milestone payments up to &nbsp;$3.6 billion;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total up to $5.33 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additional potential single digit royalties based on annual net sales of the products.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/astrazeneca-enters-into-collaboration-with-cspc.html\">https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/astrazeneca-enters-into-collaboration-with-cspc.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-06-13 (June 13, 2025) Licensor: CSPC (CSPC Pharmaceuticals Group Limited.&nbsp;, China) Licensee: AstraZeneca\uff08UK\uff09 Collaboration &hellip; <a title=\"[Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug research\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/106.html\"><span class=\"screen-reader-text\">[Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug research<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-106","post","type-post","status-publish","format-standard","hentry","category-china-tech-corp"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=106"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/106\/revisions"}],"predecessor-version":[{"id":108,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/106\/revisions\/108"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}